GE HealthCare begins phase 2/3 trial for manganese-based MRI contrast agent
Tweet Send to a Friend
GE HealthCare Technologies Inc. (NASDAQ: GEHC) announced the first patient has been dosed in its Phase 2/3 LUMINA clinical trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
